08:57 AM EST, 12/11/2024 (MT Newswires) -- AnaptysBio ( ANAB ) said Wednesday that it would discontinue further investment in experimental therapy ANB032 after a phase 2b trial in moderate-to-severe atopic dermatitis or eczema did not meet the primary and secondary endpoints.

The company said it would focus its resources and capital on its other investigational autoimmune drugs.

AnaptysBio ( ANAB ) said it expects to report top-line phase 2b data for rosnilimab in rheumatoid arthritis in February and top-line phase 2 data in ulcerative colitis in Q1 of 2026.

Shares of the company were up more than 2% in recent premarket activity.